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The cellular toxicology of mitragynine, the
dominant alkaloid of the narcotic-like herb,
Mitragyna speciosa Korth
Nor Aini Saidin,†a Elaine Holmes,a Hiromitsu Takayamab and Nigel J. Gooderham* a
Mitragyna speciosa Korth (Kratom), a herb of the Rubiaceae family is indigenous to southeast Asia. The
plant and its dominant alkaloid mitragynine (MIT) are narcotic/analgesic and illicit consumption is wide-
spread in Asia; the toxicological consequences of consumption are poorly documented. We determined
cytotoxicity of MIT on human cell lines and report dose and time-dependent stimulation and inhibition of
proliferation. Since MIT has powerful opiate-like activity, we focussed on human neuronal SH-SY5Y cell
line and found the colony forming ability of cells treated with MIT showed a dose-dependent trend for
reduced survival. Studies using metabolically competent MCL-5 cells and chemical inhibitors indicated
that CYP 2E1 and 2A6 were involved in the cytotoxicity. Cytotoxicity was preceded by cell cycle arrest
mainly at G1 and S phase. To assess whether arrest was due to DNA damage or mutation, we examined
genotoxic potential using the L5178 TK +/− mouse lymphoma assay and found that MIT was not genotoxic
at the TK locus, even at doses that were highly cytotoxic. To investigate mechanisms of MIT cytotoxicity,
we used ﬂow cytometry and annexin V with 7-amino-actinomycin D staining and show apoptosis and
necrotic activity. Apoptosis was further supported as MIT rapidly induced the activity of executioner cas-
pases 3/7. However, cytotoxicity of MIT was partially reduced by inclusion of the opioid receptor anta-
gonist naloxone, a μ and δ opioid receptor antagonist, suggesting that cytotoxicity depends in part on opioid
signalling, consistent with the known toxicity of other opiates. Based on consumption of 20 leaves per
day of Mitragyna speciosa, we estimated daily human exposure to MIT to be about 17 mg MIT for regular
consumers, potentially giving plasma concentrations in of 10−9 to 10 −7 M. Importantly, fatalities after
kratom consumption have been reported to occur in individuals with blood mitragynine concentrations
of between 0.45–1.0 μM, substantially lower than the threshold of toxicity predicted from this in vitro
report. Clearly the implications of these ﬁndings to humans consuming Mitragyna speciosa leaves will
require further study, but individuals taking large quantities of these opiate-like materials may be at risk,
especially those who have a high CYP2E1 activity, such as heavy alcohol users.
Introduction
The use of traditional medicines from natural products,
mainly plants, is increasing in developing countries. Although
the safety and eﬃcacy of most of the traditional medicines
used in humans are yet to be thoroughly investigated, people
still turn to them due to availability and cost. Mitragyna spe-
ciosa Korth, also known as ‘kratom’, is a traditional plant
having unique therapeutic constituents; it is found growing in
Malaysia, Thailand and neighbouring countries. Mitragyna spe-
ciosa Korth plant, especially its leaves, has long been con-
sumed by local farmers and labourers who chew the fresh
leaves,smoke the dry leaves or drink as a tea suspension 1 or
even eat it in the form of resin, for stimulant eﬀects. The plant
has unique dual opioid properties which exert a stimulant
eﬀect at low doses and sedative and analgesic eﬀects at the
higher doses in humans.2,3 This characteristic of the plant has
led to it being highly abused by drug addicts. 4 The chemistry
and pharmacology of the leaves of this plant, especially the
dominant alkaloid, mitragynine (MIT, Fig. 1), is known to
include opioid-like agonistic eﬀects. 1,5,6 MIT was reported to
exert antinociceptive and anti-tussive eﬀects upon oral, sub-
cutaneous and intraperitoneal administration to rodents. 7
Recently the MIT congener, 7-hydroxymitragynine was found
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to have potent opioid-like eﬀects both in vitro and in vivo. 8 In
contrast to this established pharmacology, the toxicological
consequences of exposure to these compounds are poorly
documented. Drug addicts using the plant and its extracts
report dry mouth, emaciated body with an unhealthy complex-
ion (dry skin and dark lips, resembling hepatic face), frequent
urination, constipation coupled with small and blackish
stools, loss of appetite and weight loss, central nervous system
depression, reduced smooth muscle tone and for heavy users,
prolonged sleep.2,3 In Malaysia, the possession of any form of
the plant by the public is illegal. However, in other parts of the
world, kratom is currently not scheduled. The availability of
kratom over the internet has attracted use of the plant as self-
treatment in opioid withdrawal and chronic pain. 4 Recently,
there have been several reported fatalities associated with con-
sumption of Kratom.9–11 The reason for these deaths is not
understood but MIT toxicity is implicated. In view of this and
the lack of understanding of the toxicity of MIT, we have exam-
ined the cytotoxicity potential of MIT, the dominant alkaloid
of Mitragyna speciosa in human cell lines and the mechanisms
involved in this toxicity.
Materials and methods
Chemicals
Pure mitragynine (>98% purity) was prepared from Mitragyna
speciosa as previously described6 and identity confirmed by
comparison to an authentic reference sample (from the Insti-
tute of Medical research, Kuala Lumpur, Malaysia). Mitra-
gynine (>98%) was dissolved in ethanol and filtered through
sterile 0.45 µM filter for cell culture studies. Metabolic inhibi-
tors diethyldithiocarmate (DED), a CYP 2A6 inhibitor and
3-amino-1,2,4-triazole (ATZ), a CYP 2E1 inhibitor were pur-
chased from Sigma-Aldrich Company (Poole, England). For
flow cytometry analysis, Alexa Fluor® 647-Annexin V conjugate
staining kit, 7-Amino-actinomycin D (7-AAD) dye and HEPES
buﬀer were obtained from Invitrogen, U.K. The opioid receptor
antagonists, naloxone, naltrindole and cyprodime hydro-
bromide were purchased from Sigma-Aldrich, U.K. For the
caspase studies,the Apo One® Homogenous Caspase 3/7 kit
was purchased from Promega, U.K. The fluorescent dye, 2,7-
dichlorofluorescein diacetate (DCFH-DA) and hydrogen per-
oxide (H2O2) for ROS assay were purchased from Sigma-
Aldrich, U.K.
Cell line and conditions
The SH-SY5Y and HEK 293 cell lines were purchased from the
European Collection of Cell Cultures (Salisbury, UK) and the
MCL-5 cell line was purchased from Gentest Corp. (MA, USA).
The mouse lymphoma L5178Y TK +/− cells were a kind gift
from Dr M. O’Donovan AstraZeneca (Macclesfield, UK). MCL-5
cells, a metabolically competent human lymphoblastoid cell
line stably transfected with plasmids encoding CY1A2, 2A6,
2E1, 3A4, epoxide hydrolase and constitutive 1A1 were cultured
in RPMI 1640; HEK 293, a human embryo kidney cell line was
cultured in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) and SH-SY5Y cells, a human neuroblastoma cell line
was cultured in high glucose Glutamax® DMEM. All media
were from Invitrogen Corporation (Paisley, Scotland, UK).
MEM, DMEM and Glutamax® DMEM media were sup-
plemented with 10% fetal bovine serum (FBS), 2 mM L-glut-
amine and 100 units of penicillin/streptomycin, all from
Invitrogen. RPMI 1640 was supplemented with 9% horse
serum, 2 mM L-glutamine, 2 mM histidinol and 100 units of
penicillin/streptomycin, also from Invitrogen. Routinely, cells
were maintained at 37 °C, in a humidified atmosphere of
95%/5% air/CO2. Adherent cell lines, HEK 293 and SH-SY5Y
cells were harvested by trypsinisation with trypsin-EDTA
(Invitrogen) and centrifugation, and subcultured appropriately;
suspension cell lines, MCL-5 cells were harvested by centrifu-
gation. Histidinol (2 mM) was added to every subculture of
MCL-5, for plasmid maintenance.
Cell viability (trypan blue exclusion assay)
In order to estimate the percentage of dead cells after treat-
ment with MIT, cells were harvested then stained with trypan
blue solution (0.4%) and the number of trypan blue-positive
(dead cells) and trypan blue negative (live) cells were counted
with a haemocytometer under a light microscope.
In some experiments, the role of opioid receptors in med-
iating MIT toxicity was investigated; three opioid receptor
antagonists were used; naloxone (1 μM, µ and δ opioid antag-
onist), naltrindole (1 μM, δ opioid antagonist) and cyprodime
hydrobromide (1 μM, µ opioid antagonist).
Colony survival (clonogenicity assay)
For survival studies, cells (SH-SY5Y and HEK 293 cells) treated
with MIT, were trypsinised, centrifuged and seeded at 100 cells
per well in 6 well plates in 2 ml drug-free medium and incu-
bated for a period of 6–7 days. The wells were stained with
methylene blue (1% in 50% methanol) and colonies that con-
tained 50 or more cells were scored as survivors. Relative cell
survival was expressed as percentage of appropriate vehicle-
treated controls. In some experiments, the eﬀect of metabolic
activation on MIT cytotoxicity was also examined using Aro-
chlor-induced rat liver S9 (9 µg protein).
Fig. 1 The structure of mitragynine.
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Flow cytometry analysis (cell cycle analysis)
Treated SH-SY5Y cells were harvested by routine trypsinisation,
washed with PBS and fixed in ice-cold 70% ethanol overnight.
The fixed cells were then collected by centrifugation (1200 rpm
for 5 min) and re-suspended in staining solution containing
5 mg ml −1 propidium iodide (PI), 10 µg µl−1 RNase and 0.1%
triton-X100 and incubated at 37 °C for 30 minutes. Samples
were analysed using the Cellquest Pro software on a Becton
Dickinson FACSCalibur flow cytometer. For each sample,
30 000 events were collected and aggregated cells were gated
out of the analysis. The percentage of cells at diﬀerent phases
of the cell cycle was determined using ModFit LT MAC 3.1 soft-
ware. PI was excited at 488 nm, and the fluorescence analysed
at 620 nm.
Immunoblot analysis
Cell lysates (10 μg protein) were resolved by SDS-polyacryl-
amide gel electrophoresis and electroblotted onto nitrocellu-
lose membrane. Blots were blocked by incubation in 5% low
fat dried milk in 25 mM phosphate buﬀered saline and 0.1%
tween 20 for 45 minutes at room temperature. The nitrocellu-
lose blot was incubated with primary antibody overnight at
4 °C, followed by secondary antibody conjugated to horse-
radish peroxidase for 1 h at room temperature. Detection was
achieved using ECL kit (Amersham Life Science, UK). The anti-
bodies against p53 (1 in 2000 dilution) were purchased from
Santa Cruz, (California, USA) and the β-actin antibody (1 in
20 000 dilution) was purchased from Sigma-Aldrich (Poole,
England). The quantitation of each immunoblot obtained was
carried out using a UMAX powerlook 1100 scanner, and the
p53 band intensity normalised to β-actin was analysed using
Image J version 1.37 software.
The L5178Y TK+/− mouse lymphoma cell assay
The mouse lymphoma L5178Y TK+/− cells were maintained in
RPMI 1640 Glutamax-1 medium containing 3.0 mM L-glut-
amine and 25 mM HEPES and supplemented with 1.8 mM
sodium pyruvate, 50 µg ml−1 streptomycin: 50 IU ml −1 penicil-
lin, 0.1% pluronic F-68 and 10% (v/v) heat inactivated donor
horse serum. The cells were treated prior to use in the assay
with thymidine (9 µg ml −1), hypoxanthine (15 µg ml−1), metho-
trexate (0.3 µg ml−1) and glycine (22.5 µg ml −1) to maintain a
low and stable background mutant frequency. 7,12-Dimethyl-
benz[a]anthracene (DMBA) was used as positive control in the
presence of aroclor induced rat liver S9-mix at a final concen-
tration of 5 μg ml −1, dissolved in DMSO. Methyl methanesulf-
onate (MMS) dissolved in dimethyl sulphoxide was used as a
positive control in the absence of S9-mix at final concentration
of 20 μg ml −1. The assay was performed in a 96 well plate
format as described by Clements 12 and Moore et al.13 After
treatment with MIT (3 h in the presence of aroclor induced rat
liver S9 or 24 h in the absence of S9), cells were harvested.
Treated cells (106) were suspended in normal culture media for
48 h to permit expression of the TK −/− phenotype. An aliquot
of cell suspension was then plated out for viability in a 96 well
plate at a density of 1.6 cells per well. For mutant selection, tri-
fluorothymidine was added to the cell suspension to give a
final concentration of 4 mg ml −1, cells were added to each well
of a 96 well plate at a density of 2000 cells per well. The plates
were incubated for 12 days at 37 °C in a humidified atmos-
phere of 5% CO 2. At the end of this period, wells containing
no viable cells were identified and counted. The mutant fre-
quency (MF), plating eﬃciency and relative total growth (RTG)
were determined as previously described.12,13
Annexin V conjugates/7-AAD double staining for apoptosis
detection
Double staining for cellular DNA using Alexa Fluor® 647-
Annexin V conjugate staining kit and 7-AAD were performed
following manufacturer’s instruction. SH-SY5Y cells (1 × 106)
in exponential growth phase were incubated for 2 hours or
overnight, and treated with various concentrations of MIT and
further incubated at 37 °C (5% CO2) for 24 hour. After harvest-
ing, cell pellets were washed with cold PBS followed by cen-
trifugation (1200 rpm.). Cells were re-suspended in Annexin-
binding buﬀer (10 mM HEPES, 150 mM NaCl and 2.5 mM
CaCl2 at pH 7.4) and then counted and the cell density
adjusted to 1 × 10 6 cells per ml. Alexa Fluor® 647-Annexin V
conjugate (5 µl) was added to each 100 µl of assay and incu-
bated at room temperature in the dark for 15 min. The
Annexin-binding buﬀer (200 µl) was added to the suspension
and kept on ice followed by adding 2 µl/100 µl cells suspension
of the 7-AAD (1 mg ml −1 in phosphate buﬀer). The cells were
then incubated on ice for 5 minutes until data acquisition
with a Becton Dickinson FACSCalibur flow cytometer using
CellQuest Pro software. The fluorescence of AlexaFluor®647-
Annexin V conjugate was measured at 650 nm excitation and
665 nm emission and 7-AAD at 488 nm excitation and 620 nm
emission. Thirty thousand (30 000) cells were analysed for each
treatment using FLOW JO 8.1.1 software.
Apo One® homogenous caspase 3/7 assay
SH-SY5Y cells (105 cells per well of six well plates) were treated
with MIT for 4 h or 18 h. After incubation, cells were harvested
by trypsinisation and centrifugation. The assay was performed
according to the manufacturer’s instructions (Promega, USA).
After cell counting, 20 000 cells in 100 µl volume were trans-
ferred to 96 well black plates. One hundred microliter of
caspase 3/7 reagents (mixture of caspase substrate and caspase
buﬀer) was added to each well, shaken for 30 seconds and
incubated at room temperature. Serial fluorescence readings
were performed over at least 1 h using a plate reader at 485 nm
excitation and 520 nm emission.
Reactive oxygen species (ROS) analysis
ROS assay was carried out using SH-SY5Y cells and the fluo-
rescent dye 2,7-dichlorofluorescein diacetate (DCFH-DA).This
dye diﬀuses through the cell membrane and is hydrolysed
enzymatically by intracellular esterases to form monofluore-
scent dichlorofluorescein (DCFH) in the presence of ROS. The
intensity of the fluorescence is proportional to the levels of
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intracellular ROS.14 Briefly, SH-SY5Y cells (2 × 103 cells per
well) in 24 well plates were cultured overnight, then the
medium was aspirated and washed with PBS to remove all
traces of albumin (a free-radical quencher). PBS (2 ml) was
added to each well followed by freshly prepared DCFH-DA dye
dissolved in DMSO (10 μL of 100 µM) under subdued lighting.
In some experiments, anti-oxidant, N-acetyl-L-cysteine (NAC)
(5 mM) was also added. After 30 minutes, cells in each well
were treated with H2O2 ( positive control) or MIT and the fluo-
rescence was measured using a plate reader with 485 nm exci-
tation and 530 nm emission. Fluorescence readings were
continually read at 10 min intervals for up to 1 h period.
Statistical analysis
One way Analysis of variance (ANOVA)with Tukey–Kramer or
Dunnet post tests was conducted to calculate significant diﬀer-
ences where p-values of <0.05 were considered significant.
Results
Cell viability by trypan blue exclusion assay
MIT treated cells showed stimulation and inhibition of cell
proliferation that was dose and time-dependent in the human
cell lines examined (HEK 293, MCL-5 and SH-SY5Y cells)
(Fig. 2); SH-SY5Y and MCL-5 cells were more sensitive to the
treatments (Table 1). At low doses, proliferation was stimulated
in the SH-SY5Y cell line at the 24 and 48 h time points; this
was less pronounced in the HEK293 cell line. The reason for
the increased proliferative response is not clear and it should
be noted that there was considerable variability in the data. By
72 h this stimulatory eﬀect was no longer apparent. As the
dose was increased, toxicity became more evident, particularly
in the SH-SY5Y cells where survival was negligible at the
highest dose employed, irrespective of incubation period. The
eﬀect of CYP expression on MIT proliferation and toxicity
(trypan blue uptake) was examined in metabolically competent
MCL-5 cells. In preliminary experiments, ketoconazole (CYP
3A4 inhibitor at 25 µM), diethyldithiocarbamate (DED) (CYP
2A6 inhibitor at 100 µM), 3-amino-1,2,4-triazole (ATZ) (CYP
2E1 inhibitor at 25 µM) and α-naphthoflavone (CYP 1A inhibi-
tor at 25 µM) were incubated with MCL-5 cells and MIT. Only
DED and ATZ were found to alter MIT cytotoxicity (data not
shown), therefore, the eﬀect of DED and ATZ on MCL-5 pro-
liferation and cytotoxicity was examined in more detail
(Fig. 2C). Both ATZ and DED reduced toxicity at 50 µM MIT. At
100 μM MIT, ATZ showed some inhibition of toxicity, although
this was not statistically significant and DED was without
eﬀect.
Colony survival (clonogenicity assay)
The clonogenicity assay is a longer term measure that assesses
not only the eﬀects of cell death but also the ability of cells to
form a colony. As shown in Fig. 2D, under these conditions,
the inhibition of proliferation by MIT is overcome on pro-
longed culture and colony formation although there was a sig-
nificant trend for clonogenic cytotoxicity with increasing dose
( p < 0.05 for trend). Interestingly, an increased clonogenic
response of the SH-SY5Y cells at low dose MIT (0.3 μM) was
observed, although this eﬀect was not statistically significant.
Assessment of cell cycle distribution by flow cytometry
To determine whether MIT treatment could aﬀect the pro-
gression of cell cycle, treated cells were stained with propidium
iodide and analysed by flow cytometry. The DNA profiles of
SH-SY5Y cells were assessed after exposure to various concen-
trations of MIT (Fig. 3). There were no major eﬀects on the
cycle seen with doses up to 30 µM MIT for 24 h. However,
striking changes were evident at the highest dose tested, 75
µM MIT, where cells accumulated at G1 phase and the popu-
lation appeared to shift to increased fluorescence (right shift),
consistent with treated cells taking up more PI dye (Fig. 3).
Mouse lymphoma thymidine kinase (TK −/− ) gene mutation
assay
In view of the striking eﬀect on cell cycle at 75 μM, we investi-
gated the ability of MIT to damage DNA and induce mutation
using the mouse lymphoma TK assay. The results are shown
in Table 2. For this assay, a positive result is described as a MF
that is higher than the sum of Mean Control MF (77 × 10−6)
plus the standard global evaluation factor for this microplate
assay (GEF,126 × 10−6, Moore et al.13). In the presence of S9,
there was a slight increase in mutant frequency with the two
highest doses, but the mutant frequency remained within the
GEF and is therefore not considered to be a mutagenic
response. The positive control DMBA gave a clear positive
response. There was very little toxicity, assessed as the RTG,
noted under these conditions. In the absence of S9 during a
24 h incubation, MIT was dose dependently cytotoxic. Cytotoxi-
city as measured by the RTG was substantial at the highest
dose. Again, there was a small dose dependent increase in the
mutant frequency, but still within the GEF and thus the com-
pound was not considered to be mutagenic. Again the positive
control, MMS, gave a clear positive response.
Immunoblot analysis
Since the cytotoxicity of MIT was accompanied by cell cycle
arrest, it was proposed that these changes could be a result of
alteration in the expression and activation of regulatory pro-
teins such as p53. Therefore, the eﬀects of MIT on p53 protein
levels were assessed in SH-SY5Y cells.Between doses of MIT,
there was little diﬀerence in the expression of p53, however at
all concentrations of MIT there appeared to be a loss of p53
expression compared to the control group (Fig. 4).
Annexin V conjugate assay for apoptosis detection
Our preliminary observations on the toxicity of MIT indicated
that MIT induced cell morphology changes indicative of apop-
tosis with microscopic evidence of chromatin condensation, in
SH-SY5Y cells. We therefore explored the mechanisms of MIT-
induced cell death. Translocation of phosphatidylserine to the
outer plasma membrane indicates early apoptotic cell death,
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and Annexin V reactivity can be used as a marker for apoptotic
cells.15,16 The cells become reactive with Annexin V prior to the
loss of the ability of the plasma membrane to exclude the dye
7-AAD and thus detection of unaﬀected (live) cells, early apop-
totic, necrotic and late apoptotic cells is possible.17
The cell populations were gated according to four diﬀerent
quadrants (Fig. 5); Q1 represent live cells (exclude Annexin V
and 7-AAD), Q2 are Annexin V positive indicating early apop-
tosis, Q3 are Annexin V and 7-AAD positive indicating late
apoptosis/necrosis and Q4 represent necrotic cells permeable
to the 7-AAD dye.
With MIT treatment at the highest concentration tested,
75 µM, it appears that the profile was shifted to the right side
with concomitant increase of cells in Q2, Q3 and Q4 indicating
increased apoptotic and necrotic cells. This increased suscepti-
bility to dye permeability is consistent with the response
observed during cell cycle analysis using PI staining.
Involvement of executer caspases (3 and 7)
The activity of caspase 3/7 was assessed in SH-SY5Y cells
treated with MIT. With incubation of MIT for either 4 or 18 h,
at 100 µM and 300 µM MIT, there was significant activation of
caspase 3/7 activity (Fig. 6).
ROS generation in SH-SY5Y cells treated with MIT
An important mechanism whereby xenobiotics induce cell
death is through the generation of reactive oxygen species
Table 1 Eﬀect of MIT on cell growth a
IC50
Cell line MIT (μM)
SH-SY5Y 75
HEK 293 240
MCL-5 80
a IC50 values are the concentration required to reduce the relative (to
control) cell number by 50% after 24 h treatment with MIT. The values
were interpolated from cell survival curves.
Fig. 2 Cytotoxicity of MIT treated cells. A. Proliferation of HEK 293 cells with MIT treatment. B. Proliferation of SH-SY5Y cells with MIT
treatment. C. Proliferation of MCL-5 cells treated with MIT and DED (100 µM) or ATZ (25 µM) for 48 h. D. Clonogenicity of SH-SY5Y cells after MIT
treatment for 24 h. Cell number was assessed using trypan blue exclusion and clonogenicity by counting colonies. Values are the mean ± SEM of
three or four independent cultures. *P < 0.05 vs. respective MIT alone controls, ANOVA with Tukey–Kramer post test.
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(ROS).Intracellular ROS can be detected using the formation
of the fluorescent product DCFH after hydrolysis of DCGH-DA.
As shown in Fig. 7, the positive control, H2O2 generated a clear
response in the SH-SY5Y cell that was inhibited by pre-incu-
bation (30 min prior to addition of H 2O2) with NAC. Similar
treatments with MIT failed to induce any detectable ROS
response in this cell (Fig. 7).
Eﬀects of opioid receptor antagonists on treated SH-SY5Y cells
We considered the possibility that the toxicity of MIT may be
associated with interaction at the opiate receptor. The
SH-SY5Y cells express predominantly the µ and δ opioid recep-
tor.18 We therefore used a trypan blue assay to assess cytotoxi-
city eﬀects of MIT in the presence of selective opioid receptor
antagonists naloxone (µ and δ antagonist), naltrindole
(δ antagonist) and cyprodime hydrobromide (µ antagonist).
After 24 h of treatment, naloxone at the concentration of
1 µM successfully inhibited cytotoxicity that is evident at 100 µM
MIT (Fig. 8). In contrast naltrindole failed to oﬀer significant
protection against MIT induced cytotoxicity and cyprodime
hydrobromide was only partially protective (Fig. 8).
Discussion
The analgesic properties of Mitragyna speciosa plant have been
described in vitro and in vivo, mainly using crude alkaloid
extracts but also with its dominant alkaloid mitragynine (MIT)
and congeners. 19,20 These medicinal properties have been
Fig. 3 Eﬀects of MIT on the cell cycle distribution of SH-SY5Y cells. Cells were treated for 24 h with MIT. Representative histograms are shown and
values of each phase of the cell cycle are the mean of the three independent experiments.
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reported for extracts of the leaves of this plant but not from
other species of Mitragyna. Several countries like Thailand,
Myanmar, Malaysia and Australia have made possession of the
plant illegal, due to its narcotic properties, yet preparations of
the plant are available for sale over the internet. The popularity
of this herb in Western culture is increasing and some individ-
uals are now taking it for self-treatment of chronic pain and as
an aid to opioid withdrawal. 4 The potential toxicity of MIT and
of other products derived from Mitragyna speciosa is currently
poorly documented and recently there have been several
reported fatalities associated with consumption of Kratom. 9–11
The reason for these deaths is not understood but MIT toxicity
is implicated. Therefore an in vitro toxicological assessment of
its dominant alkaloid MIT was undertaken. MIT was found to
exert dose-dependent cytotoxic eﬀects to human cell lines. We
demonstrated that MIT was toxic to all three cell lines exam-
ined and the human neuronal SH-SY5Y cell was chosen for
further study as neuronal tissue is a high probability target for
opiate-like compounds such as MIT. The concentration of MIT
required to reduce the relative (to control) cell number by 50%
(IC50) following 24 h treatment of SH-SY5Y cells was 7.5 × 10−5
M. In contrast, we noted that low doses of MIT (3 × 10 −7 M)
stimulated cell proliferation during the first 48 h but this
eﬀect was lost at the 72 h time point. The reason for this
stimulation of proliferation is not clear, especially since other
classical opiate agonists, such as morphine, suppress rather
than stimulate proliferation. 21
Many xenobiotics undergo metabolic activation in the
process of exerting their cytotoxicity eﬀects. CYP proteins are
key enzymes involved in oxidative xenobiotic metabolism,
therefore we examined if metabolism was involved in MIT cyto-
toxicity using MCL-5 cells (metabolically competent and
express-CYP1A1, 1A2, 2A6, 2E1, 3A4 and human epoxide hydro-
lase). We compared the toxicity of MIT in MCL-5 cells in the
presence of inhibitors of the CYP enzymes. Incubations in the
presence of inhibitors of CYP3A4 and 1A1 failed to aﬀect tox-
icity, but inhibitors of 2E1 and 2A6 did protect against MIT
toxicity, suggesting involvement of these enzymes.
To further characterise the nature of the cytotoxicity of MIT,
we examined SH-SY5Y cellcycle distribution, using flow cyto-
metry.16,17SH-SY5Y cells treated with MIT appeared to be resistant
to cell cycle eﬀects except at the highest dose tested, 75 µM,
where there was evidence for a G1 arrest. An unexpected obser-
vation in these experiments was the right-shifting of the DNA
profiles which was pronounced in the high dose of MIT. This
phenomenon implies that the cells have taken up more PI, thus
increasing the DNA staining intensity. The explanation for this
phenomenon is unknown however, it could reflect plasma
membrane integrity being compromised by the treatment, thus
creating pores or increased membrane permeability.
In view of the eﬀect on cell cycle at 75 μM, we investigated
the ability of MIT to damage DNA and induce mutation using
the well-established L5178 TK+/− mouse lymphoma cell assay.
Under the conditions of the ICH agreed guidelines for this
assay,MIT was not found to be genotoxic in the presence or
absence of a metabolic activation system, although substantial
toxicity was noted at the 75 μM concentration when RTG was
lowered to 17%.
Since the cytotoxicity of MIT was accompanied by cell cycle
arrest, it was proposed that these changes could be a result of
alteration in the expression and activation of regulatory pro-
teins such as p53. In fact immunoblotting indicated the loss
of the P53 protein with MIT treatment. The mechanism of this
loss is not obvious, but could involve compromised membrane
integrity. Consistent with this, the right shift of the DNA pro-
files (increased PI staining) in the flow cytometry experiments
indicates a mechanism in which the dyes could diﬀuse more
easily into the cell.
Table 2 Genetic toxicology of MIT in L5178 TK +/− mouse lymphoma
cells
Substance
Concentration
(μM) RTGa
Mutantsb TK−/−
(MF)
3 h incubation +S9
MIT 0 100 77
12.5 99 72
25l 91 71
50 96 106
75 92 101
DMBA (positive control) 1 μg ml−1 78 550
24 h incubation (no S9)
MIT 0 100 88
12.5 74 56
25 81 104
50 37 167
75 17 114
MMS (positive control) 5 μg ml−1 87 590
a RTG relative total growth (%) – measure of cell growth relative to
control. b MF mutant frequency (TK −/− mutants per 106 clone forming
cells).
Fig. 4 P53 expression in SH-SY5Y cells treated with MIT for 24 h. A
representative immunoblot is shown. For quantitation, bars are normal-
ised to the β-actin controls and are the mean of three independent
experiments with SEM.
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Further flow cytometry analysis using double staining with
Annexin V conjugates and 7-AAD supported this MIT-induced
membrane permeability,with the dyes being more readily taken
up by treated cells. These experiments further indicated that most
of the treated cells were necrotic and late apoptotic populations.
The ability of cysteine proteases,caspases22,23 to perform
proteolytic cleavage at defined aspartate acid residues in various
cellular substrates is an established marker of apoptosis.24
We examined the involvement of executioner caspases (caspase
3 and 7) in MIT cytotoxicity in SH-SY5Y cells and found signifi-
cant increases in caspases 3 and 7 activities at both concen-
trations of MIT tested. This finding suggests that the mode of
the cell death of MIT treated cells involves caspase 3 and 7
activation pathway and is indicative of apoptosis.
Fig. 5 Flow cytometry assessment of apoptosis and necrosis of SH-SY5Y cells after 24 h treatment with MIT. Treated cells were stained with Alexa
Fluor® 647-Annexin V conjugate and 7-AAD. Four quadrants (Q) representing normal cells (Q1), early apoptosis cells (Q2), late apoptotic/necrotic
cells (Q3) and necrotic cells (Q4). Table shows mean ± SEM values of % cells in each quadrant from 3 independent cultures ** signiﬁcantly diﬀerent
from respective control, P < 0.01, ANOVA with Dunnet post test.
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Under normal circumstances, the low levels of ROS gene-
rated by mitochondria as a normal by-product of oxygen
metabolism are usually removed by an abundance of
endogenous free radical scavengers such as enzyme superox-
ide dismutases, glutathione and other cellular antioxidants
such as ascorbic acid and vitamin E. 25,26 However xenobiotic
insult, which causes mitochondrial malfunctions, may
lead to generation of ROS in higher levels thus triggering
oxidative stress, lipid peroxidation and finally cell death.
In the present study, MIT treatment failed to induce ROS,
suggesting this was not a mechanism of the apoptotic cell
death noted here.
MIT has been shown to exert its biological activities via
opioid receptors mainly µ-, and δ- and to a lesser extent
κ-opioid receptors. 5,27,28 The opioid analgesic, morphine is
also known to exert its biological activities mainly via µ-opioid
and also δ- and κ-opioid receptors 29 however the selective
binding site of MIT for µ-receptor is reported to be of a
diﬀerent subtype from morphine. 5 Cell death induced by
opioids is associated with their opioid receptor signalling,
such as neuronal apoptosis induced by morphine due to
opioid receptor desensitisation and uncoupling to pertussis
toxin (PTX)-sensitive inhibitory G protein (Gi). 30 Additionally,
morphine has been shown to induce cell cycle block and apop-
tosis in MCF-7 and MDA-MB231 mammary cancer cells that
was naloxone sensitive;31 inhibited growth and proliferation
and induced cell cycle arrest in MGC-803 gastric cells;32 inhib-
ited proliferation and increased apoptosis of neural progenitor
cells that was reversed by naloxone, and the authors suggested
the involvement of the μ opioid receptor. 33 Thus this infor-
mation poses the question of whether the opioid receptors
mediating the biological activity of the Mitragyna speciosa
Korth plant may also mediate the MIT induced toxicity or cell
death. Opiate receptor antagonists should therefore protect
against MIT induced cell death. As anticipated, naloxone
(µ- and δ-receptor antagonist) and cyprodime hydrobromide
(µ- receptor antagonists) successfully gave protection against
Fig. 6 Activity of executor caspases 3/7 in SH-SY5Y cells treated with
MIT for 4 h or 18 h incubation. Values are mean ± SEM for 3 indepen-
dent cultures. Signiﬁcantly diﬀerent from respective control, **P < 0.01,
ANOVA with Dunnet post test.
Fig. 7 Measurement of ROS with DCFH-DA in SH-SY5Y cells treated
with H 2O2, or MIT with or without NAC. Fluorescent readings are nor-
malised to the respective control group. Values are mean ± SEM for 3
independent cultures.
Fig. 8 Trypan blue exclusion assay of SH-SY5Y cells after 24 h treatment with (A) MIT ± Naloxone (N), (B) MIT ± naltrindole (Nalt), C) MIT ± Cypro-
dime hydrobromide (C). Values are mean ± SEM for 3 independent cultures. Signiﬁcantly diﬀerent from respective control, *P < 0.05, ANOVA with
Bonferroni post test.
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MIT toxicity. Interestingly the opiate agonist etorphine (exhibits
activity through the μ, κ and δ opioid receptors) inhibited the
cell growth of SK-N-SH cells, yet the inhibition was not pre-
vented by naloxone, suggesting that the eﬀects of etorphine
might not be mediated by a classical opioid receptor. 34 These
observations indicate that further work is required to define
the mechanisms involved in the toxicity of MIT.
Based on consumption of 20 leaves per day of Mitragyna
speciosa, the estimated daily human exposure to MIT is about
17 mg for regular consumers.3 Assuming total body distri-
bution of the drug (70 kg BW per person), in vivo concen-
trations are probably in order of 10−9 to 10−7 M MIT.
Extrapolating cell based in vitro studies to whole animal
studies require huge assumptions, but since the in vitro tox-
icity of MIT is not obvious until ≥75 µM, human consumption
of Mitragyna speciosa Korth leaves at pharmacologically active
doses would appear to be substantially lower than the
threshold of toxicity predicted from this in vitro study.
However, these assumptions do not take into account local
concentrations of MIT in the GI tract after consumption,
which could be significantly higher. The reported GI disturb-
ance noted in Kratom addicts could reflect this potential tox-
icity and there have been several reports of fatalities associated
with kratom consumption. 9–11 In these reports, the blood con-
centrations of MIT ranged from 0.48–1.5 μM, which is fifty
fold lower than the concentrations required to produce overt
toxicity in the present in vitro toxicity study. Additionally, the
study by McIntyre et al. 9 reported that liver concentrations of
MIT (1.08 μM) were twice the blood levels. Although these
reported fatalities were complicated by the detection of other
drug entities, MIT was implicated as contributing to the
deaths.
Conclusions
Based on the current findings MIT has potential to cause cyto-
toxicity to mammalian cells. Since MIT is the dominant alka-
loid found in Mitragyna speciosa Korth (Kratom), human
addiction to Kratom is potentially harmful. The main target
system of MIT pharmacology is the central nervous system and
our studies with the human neuroblastoma cell line SH-SY5Y
indicate that such cells are susceptible to MIT cytotoxicity,
although MIT was found to exert dose dependant cytotoxicity
eﬀects in all human cell lines examined.
The cytotoxicity events are initially seen as cell cycle arrest
then proceed to cell death with increasing dose of MIT. In
addition, the metabolism studies also suggest that CYP 2E1
and possibly 2A6 activity appeared to be involved in MIT cyto-
toxicity. From the human perspective, if Mitragyna speciosa
leaves were to be ingested by individuals with elevated CYP
2E1 activity such as high consumers of alcohol, the toxicity of
Mitragyna speciosa leaves and extracts could be potentiated.
This is potentially of significance since the local concentration
of MIT in the GI tract after consumption of Mitragyna speciosa
is likely to be higher than systemic exposure; an additional
susceptibility factor is that the GI tract is known to express
CYP2E1. This is consistent with the GI disturbance noted
amongst Kratom addicts. Of particular importance is the
reported fatalities associated with kratom consumption, where
the blood concentrations of MIT were in the μM range. This is
significantly lower than the levels of MIT required to induce
toxicity we report here in our in vitro mechanistic studies and
clearly the potential for MIT to cause toxicity in vivo warrants
further investigation.
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